ReviewEmerging infectious diseases2021
Coccidioidomycosis and COVID-19 Co-Infection, United States, 2020.
Review in Emerging infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Impacts of land use and fallowing on coccidioidomycosis incidence in California: A population-based longitudinal study.Science advances · 2026Article
- Coccidioidomycosis Exposure Assessed by Skin Testing and Environmental Factors in Baja California, Mexico.Journal of fungi (Basel, Switzerland) · 2026Article
- Coccidioidomycosis-Attributable Death in the United States: An Analysis of Cases Reported on Death Certificates, 2018-2023.Journal of fungi (Basel, Switzerland) · 2025Article
- Coccidioidomycosis: a growing global concern.The Journal of antimicrobial chemotherapy · 2025Review
- The Burden of Hospital Illness Associated with Disseminated Versus Isolated Pulmonary Coccidioidomycosis in the United States.Journal of fungi (Basel, Switzerland) · 2025Article
- Developing a Coccidioides posadasii and SARS-CoV-2 Co-infection Model in the K18-hACE2 Transgenic Mouse.Communications medicine · 2024Article
- A microbial risk assessor's guide to Valley Fever (Coccidioides spp.): Case study and review of risk factors.The Science of the total environment · 2024Review
- Impetiginous Cutaneous Leishmaniasis after COVID-19 Infection in a Patient with Poor Cardiac Profile: A Case Report and Literature Review.Tropical medicine and infectious disease · 2023Article
- Coccidioidomycosis and Host Microbiome Interactions: What We Know and What We Can Infer from Other Respiratory Infections.Journal of fungi (Basel, Switzerland) · 2023Review
- COVID-19 in patients with paracoccidioidomycosis.PLoS neglected tropical diseases · 2023Review
- Diagnosis and Treatment of Pulmonary Coccidioidomycosis and Paracoccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2023Review
- Diagnosis of Legionnaires' Disease Assisted by Next-Generation Sequencing in a Patient with COVID-19.Infection and drug resistance · 2023Article
- Comparative Mask Protection against Inhaling Wildfire Smoke, Allergenic Bioaerosols, and Infectious Particles.International journal of environmental research and public health · 2022Article
- Article
- Notes From the Field: Coccidioidomycosis Outbreak Among Wildland Firefighters - California, 2021.MMWR. Morbidity and mortality weekly report · 2022Article
- Third Case of Visceral Leishmaniasis in COVID-19: Mini Review Article.Pathogens (Basel, Switzerland) · 2022Review
- Update on the Epidemiology, Diagnosis, and Treatment of Coccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2022Review
- Coccidioidomycosis and COVID-19 Infection. An Analysis from a Single Medical Center Within the Coccidioidal Endemic Area.Mycopathologia · 2022Article
- Current Landscape of Coccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2022Review
- Coccidioidomycosis Cases at a Regional Referral Center, West Texas, USA, 2013-2019.Emerging infectious diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
We review the interaction between coronavirus disease (COVID-19) and coccidioidomycosis, a respiratory infection caused by inhalation of Coccidioides fungal spores in dust. We examine risk for co-infection among construction and agricultural workers, incarcerated persons, Black and Latino populations, and persons living in high dust areas. We further identify common risk factors for co-infection, including older age, diabetes, immunosuppression, racial or ethnic minority status, and smoking. Because these diseases cause similar symptoms, the COVID-19 pandemic might exacerbate delays in coccidioidomycosis diagnosis, potentially interfering with prompt administration of antifungal therapies. Finally, we examine the clinical implications of co-infection, including severe COVID-19 and reactivation of latent coccidioidomycosis. Physicians should consider coccidioidomycosis as a possible diagnosis when treating patients with respiratory symptoms. Preventive measures such as wearing face masks might mitigate exposure to dust and severe acute respiratory syndrome coronavirus 2, thereby protecting against both infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.